Back to Search
Start Over
A Phase I Study of the Antimetabolite (E)-2'-Fluoromethylene-2' - Deoxycytidine (MDL 101,731) Administered as a Twice-Weekly Infusion.
- Source :
- Cancer Journal; Sep/Oct2000, Vol. 6 Issue 5, p309, 7p, 2 Charts
- Publication Year :
- 2000
-
Abstract
- Highlights the results of a phase I trial of (E)-2-fluoromethylene-2-deoxycytidine infusion in humans with advanced cancer. Maximum tolerated dose and the dose-limiting toxicities of the drug when administered on a twice-weekly schedule; Ribonucleotide reductase; Epithelial malignancies.
- Subjects :
- CANCER chemotherapy
ANTIMETABOLITES
DRUG therapy
Subjects
Details
- Language :
- English
- ISSN :
- 15289117
- Volume :
- 6
- Issue :
- 5
- Database :
- Supplemental Index
- Journal :
- Cancer Journal
- Publication Type :
- Academic Journal
- Accession number :
- 3736509